1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 71610-030
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Divalproex Sodium NDC 71610-030 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 250mg - 71610 030 60

Bottle Label 250mg - 71610 030 60

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Divalproex Sodium Structural Formula - image 03

Divalproex Sodium Structural Formula - image 03

Figure 1: Proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - image 04

Figure 1: Proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - image 04

This appears to be a chart showing the rate of reduction in CP$ (unspecified abbreviation) for patients with different degrees of improvement, no change, and worsening. The vertical axis appears to be percentage points, with improvement and worsening both labelled with arrows going up and down respectively. However, since there is no further context or explanation, the purpose and meaning of this chart cannot be determined with certainty.*

Figure 2: Proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study - image 05

Figure 2: Proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study - image 05

This appears to be a table showing percentages of patients receiving different doses of Divalproex Sodium with delayed release. The table shows various percentages of doses ranging from low to high and indicates a higher percentage of patients with high dose Divalproex Sodium with delayed release. There also seems to be a comparison between the high dose and low dose treatments, and a notation for "No Change".*

Figure 3: Mean Reduction in 4-Week Migraine Headache Rates - image 06

Figure 3: Mean Reduction in 4-Week Migraine Headache Rates - image 06

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.